Industry Viewpoints: Effectively Outsourcing Early Phase Clinical Trials

From ClinicalTrialsArena.com
By Elizabeth Williams 15AUG2018

CTA’s Elizabeth Williams catches up with Jeffrey Hausfeld, CMO, BioFactura, on the complexities of carrying out early phase studies.

<Read Full Article>

August 15, 2018 BioFactura In The News

About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.